Background The ORIENT-15 double-blind randomized controlled trial demonstrated that the addition of sintilimab to … this analysis, we sought to evaluate the cost-effectiveness of sintilimab as a first-line treatment for locally advanced or … cost-effectiveness analysis comparing chemotherapy alone with sintilimab for locally advanced or metastatic OSCC patients …

-11 study demonstrated a signifcant progression-free survival and overall survival for sintilimab plus chemotherapy in … the current study was to evaluate the cost efectiveness of sintilimab plus chemotherapy versus Platinum-based chemotherapy … verify the robustness of the base-case analysis results. Results: Sintilimab plus chemotherapy provided an additional 0 …

-11 study demonstrated a signifcant progression-free survival and overall survival for sintilimab plus chemotherapy in … the current study was to evaluate the cost efectiveness of sintilimab plus chemotherapy versus Platinum-based chemotherapy … verify the robustness of the base-case analysis results. Results Sintilimab plus chemotherapy provided an additional 0 …